Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,116
Recruiting: 10,894
Ph III recruiting: 1,280
Growth YoY: +12%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,163)

clinicaltrialsPublishedShowing 551–600 of 8,372 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05298423	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006)	completed	Phase 3	610	Merck Sharp & Dohme LLCINDUSTRY	25	Aug 28, 2026	clinicaltrials
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA)	recruiting	Phase 3	365	Nuvation Bio Inc.